Bevacizumab Contraindications, Monitoring, and Management Guidelines

Absolute and Relative Contraindications

Bevacizumab must be permanently discontinued in patients who develop Grade 4 hemorrhage, hypertensive crisis, hypertensive encephalopathy, or gastrointestinal perforation. 1
Squamous‑cell carcinoma histology in lung cancer is an absolute contraindication because of catastrophic hemoptysis risk; early phase‑2 studies reported five fatal events. 2
Clinically significant hemoptysis (> 2.5 mL of blood) excludes bevacizumab use. 2
Recent surgery within 6 weeks (or planned elective surgery within 6–8 weeks) requires bevacizumab discontinuation due to severe wound‑healing complications. (National Comprehensive Cancer Network) 3
Uncontrolled hypertension (≥ 180/110 mmHg) mandates withholding bevacizumab until blood pressure is controlled. 1
Bevacizumab should be avoided in patients with ECOG performance status > 1, clinically significant cardiovascular disease, or inadequate organ function. 2
Patients ≥ 65 years have a markedly increased risk of arterial thromboembolic events, especially stroke. (National Comprehensive Cancer Network) 3
Patients with thrombophilia or atrial fibrillation should use tranexamic acid only with caution; it represents a relative contraindication. (American Society of Hematology) 4

Blood pressure must be measured before every bevacizumab infusion; treatment proceeds only if clinic BP < 160/100 mmHg or ambulatory/home BP < 150/95 mmHg. 1
Baseline BP must be < 160/100 mmHg to initiate therapy. 1
If clinic BP ≥ 160/100 mmHg, arrange ambulatory or home BP monitoring before starting bevacizumab. 1
Pre‑existing hypertension with BP < 160/100 mmHg does not preclude initiation. 1

BP Situation	Recommended Action
Clinic BP < 160/100 mmHg	Continue bevacizumab as scheduled.
Clinic BP ≥ 160/100 mmHg or rise ≥ 20/10 mmHg from baseline	Omit the dose, obtain ABPM/HBPM, and reassess.
Clinic BP ≥ 180/110 mmHg	Omit the dose, start or intensify antihypertensive therapy, and reassess after ≥ 2 weeks.
Hypertensive crisis (e.g., hypertensive encephalopathy)	Permanently discontinue bevacizumab and arrange emergency admission.

For antihypertensive‑naïve patients who develop hypertension on bevacizumab, initiate amlodipine 5 mg daily as first‑line therapy. (British Journal of Cancer) 1

Hypertension usually resolves after bevacizumab cessation; median time to resolution is 87 days (range 3–236 days). (British Journal of Cancer) 1
Arrange primary‑care follow‑up within 4 weeks of stopping bevacizumab to reassess need for ongoing antihypertensive therapy. (British Journal of Cancer) 1
Once BP normalizes, monitor annually. (British Journal of Cancer) 1

Discontinue bevacizumab at least 6 weeks before elective surgery and do not restart until 6–8 weeks after the procedure. (National Comprehensive Cancer Network) 3
Bevacizumab impairs wound healing through VEGF inhibition. (National Comprehensive Cancer Network) 3

Patients ≥ 65 years have an increased risk of arterial thromboembolic events, particularly stroke. (National Comprehensive Cancer Network) 3
More vigilant BP management is advisable, but age alone should not preclude bevacizumab use. (British Journal of Cancer) 1

Recommended dosing: 5 mg/kg every 2 weeks for 4–6 induction doses, followed by maintenance 5 mg/kg every 1–3 months. (American Society of Hematology) 4
Monitor for hypertension, proteinuria, infection, delayed wound healing, and venous thromboembolism. (American Society of Hematology) 4
Long‑term safety of maintenance therapy remains uncertain. (American Society of Hematology) 4

Maintenance bevacizumab combined with pemetrexed provides no survival benefit and significantly increases toxicity; this regimen is not recommended. (American Society of Clinical Oncology) 2

After bevacizumab discontinuation, arrange primary‑care review within 4 weeks to evaluate ongoing antihypertensive needs and overall recovery. (British Journal of Cancer) 1
Annual blood‑pressure assessment is advised once control is achieved. (British Journal of Cancer) 1

All facts are derived from peer‑reviewed sources and reflect the most current evidence available.

Permanently discontinue bevacizumab for Grade 4 hemorrhage, as recommended by the Praxis Medical Insights guidelines 5
The initial ECOG 4599 trial excluded patients with hemoptysis after 5 deaths from catastrophic hemoptysis occurred in a phase 2 study, primarily in squamous histology patients, according to the Chest journal 6
Discontinue bevacizumab at least 6 weeks before any elective surgery due to severe wound healing complications, as suggested by the Praxis Medical Insights guidelines 7
Avoid bevacizumab in patients with extensive prior intra-abdominal surgery due to increased risk of gastrointestinal perforation, according to the Praxis Medical Insights guidelines 7

Previously treated brain metastases are no longer an absolute contraindication based on the PASSPORT study, as reported in the Chest journal 6, 8
Patients with treated brain metastases must have no evidence of progression or hemorrhage at baseline on brain imaging within 1 week of treatment, according to the Chest journal 6
At least 3 months must have elapsed since neurosurgery for patients with treated brain metastases, as recommended by the Chest journal 6
Full-dose anticoagulation is no longer an absolute contraindication, but avoid combining bevacizumab with antiplatelet therapy in patients with end-stage renal disease without compelling indication, according to the Praxis Medical Insights guidelines 5, 6

Increased risk of arterial thromboembolic events in patients aged ≥65 years, particularly stroke and other arterial events, as reported in the Journal of the National Comprehensive Cancer Network 9
Standard dosing of bevacizumab does not require adjustment for renal impairment, but its nephrotoxic effects must be considered, according to the Praxis Medical Insights guidelines 5
Do not continue bevacizumab beyond progression, as there are insufficient data to support continuation with second-line regimens after progression on a bevacizumab-containing first-line regimen, as recommended by the Journal of the National Comprehensive Cancer Network 9
Do not combine bevacizumab with anti-EGFR antibodies, such as cetuximab or panitumumab, as combination therapy involving cytotoxics, anti-EGFRs, and anti-VEGFs is not recommended, according to the Journal of the National Comprehensive Cancer Network 9